-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source | Nature Editor | Wang Duoyu Typesetting | Shui Chengwen On November 26, 2021, the World Health Organization (WHO) announced that the new mutant strain B.
1.
1.
529 was named "Omi Keron" and listed as a mutant strain of concern (Variant of Concern, VOC), that is, the new coronavirus variant with the highest risk level
.
In less than 4 weeks, Omi Keron infection has accounted for about 73% of the new coronavirus infections in the United States
.
On December 23, Nature published 5 papers on the effectiveness of vaccines and antibodies against Omicron variants of the new coronavirus
.
Existing new coronavirus vaccines and new coronavirus monoclonal antibodies (proteins that target and neutralize the new coronavirus) work by recognizing the spike protein (S protein) of the new coronavirus, which is also used by the new coronavirus to enter human cells Location
.
The Omi Keron variant has about 32 mutations in the spike protein and is expected to soon replace the currently popular Delta lineage.
However, Omi Keron’s impact on the effectiveness of existing therapies and vaccines is still unclear.
Know
.
The new crown virus Ome Keron variant showed amazing antibody escape, Columbia University David Ho (David Ho) and colleagues reported that the new crown pneumonia (COVID-19) vaccine and therapies are much less effective for Ome Keron
.
The author investigated four major new coronavirus pneumonia vaccines - Pfizer-BioNTech's mRNA vaccine, Moderna's mRNA vaccine, Johnson & Johnson vaccine, and AstraZeneca vaccine - neutralizing Omi Keron in samples from 54 participants The 54 participants were vaccinated with two complete doses of vaccine (15 of them were also vaccinated with Pfizer-BioNTech's mRNA vaccine and Moderna's mRNA vaccine booster)
.
A significant decrease in the effectiveness of anti-Omi Keron has been observed in all vaccine types, including two participants who have been infected with the new coronavirus
.
However, in Pfizer-BioNTech's mRNA vaccine or Moderna's mRNA vaccine booster samples, the reduction in antibody neutralization rate is small
.
The authors also studied the neutralizing activity of 19 monoclonal antibodies against the mutant spike protein of Omi Keron
.
The monoclonal antibodies tested include clinically approved therapeutic antibodies, such as REGN10987 (imdevimab), REGN10933 (casirivimab), COV2-2196 (tixagevimab), COV2-2130 (cilgavimab), LY-CoV555 (bamlanivimab), CB6 (etesevimab) ), Brii-196 (amubarvimab), Brii-198 (romlusevimab) and S309 (sotrovimab)
.
The results showed that 17 of the 19 monoclonal antibodies completely or partially lost their neutralizing ability
.
Only romlusevimab and sotrovimab retained their neutralizing activity
.
The author also reported four new mutations (S371L, N440K, G446S and Q493R) of the Omi Keron spike protein.
These mutations give Omi Keron stronger antibody resistance than other new coronavirus variants
.
Link to the paper: https:// The neutralizing effect of the new crown virus Omi Keron variant has a large escape from the neutralization of antibodies, Olivier Schwartz of the Pasteur Institute in France and colleagues from Belgium An individual in, isolated an Ome Keron virus and analyzed how sensitive the virus is to 9 monoclonal antibodies that are currently approved for clinical use or are still in development
.
As a result, it was found that the Omi Keron mutant strain can completely or partially resist the neutralizing effect of all monoclonal antibodies in the experiment
.
Among them, 5 kinds of antibodies (Bamlanivimab, Etesevimab, Casirivimab, Imdevimab and Regdanvimab) are not effective against Omi Keron; 2 antibodies (Cilgavimab and Andintrevimab) have a lower neutralizing activity against Omi Keron than their activity against delta.
20 times; Sotrovimab's anti-Omi Keron activity is about 3 times lower than its anti-delta activity
.
In the serum collected five months after the second injection of Pfizer-BioNTech's mRNA vaccine (16 people) or AstraZeneca vaccine (18 people), no antiviral activity against Omi Keron was detected
.
From the serum samples collected from 20 Pfizer-BioNTech mRNA vaccine third-injectors, the authors found that the neutralizing activity of Omi Keron increased by 6 times
.
In the serum of 40 recovered individuals (with a history of infection) collected 6 months or 12 months after the onset of symptoms, the neutralizing activity of Omi Keron was either very low or not
.
However, among these recovered individuals, 22 people who received a shot of Pfizer-BioNTech's mRNA vaccine had a higher neutralizing activity in their bodies than those who had received two shots of vaccine without a history of infection
.
These preliminary analyses are all based on the sera of vaccinators or those who have recovered from infection, but the authors pointed out that the sample size of these sera is small, and they only analyzed two vaccines, Pfizer-Biotech and AstraZeneca
.
However, the analysis results show that antibody therapy may need to be quickly adjusted for Omi Keron, and the vaccine booster injection may enhance the neutralizing ability of Omi Keron
.
Link to the paper: https:// Omi Keron's neutralization effect on Pfizer-BioNTech's mRNA vaccine has an obvious but incomplete escape from KwaZulu-Na, South Africa Alex Sigal and colleagues of Thar University used the plasma samples of 19 South African participants who had received two doses of Pfizer-BioNTech's mRNA vaccine to investigate whether Ome Keron had escaped from antibody neutralization
.
Six of the participants had no history of new coronavirus infection
.
The authors observed that, compared with the original strain of the virus, the neutralizing effect of Omi Keron stimulated by the vaccine was reduced by 22 times
.
However, the samples of participants who had a history of new coronavirus infection and were vaccinated retained some of the neutralizing activity against Omi Keron, and its activity level was comparable to that of participants who had only been vaccinated against the original new coronavirus strain.
The level is comparable
.
Link to the paper: https:// Broad-spectrum neutralizing antibodies can cope with the transformation of Omi Keron antigen.
The study by Davide Corti of Vir Biotechnology and colleagues shows that Omeike Evidence that Rong's immune escape ability may be stronger than the previous new coronavirus lineage
.
They tested the binding of the Omi Keron receptor binding domain (RBD) to the human ACE2 receptor-RBD is a part of the spike protein that can help the new coronavirus enter the host cell, and the ACE2 receptor is a major part of RBD Combine goals
.
Studies have shown that compared with the original isolated strain of the new crown, the binding affinity of Omi Keron's RBD and human ACE2 has been enhanced (increased by about 2.
4 times)
.
The author also studied the activity of monoclonal antibodies that have been approved or are under development against the new coronavirus infection against the Omi Keron pseudovirus (a new coronavirus model)
.
Among the eight therapeutic monoclonal antibodies tested in the study, most of them completely lost their neutralizing activity to Omi Keron; the effectiveness of two monoclonal antibodies (combined) was reduced by about 100 times, one monoclonal antibody ( The effectiveness of sotrovimab) has dropped by a factor of three
.
The research team also expanded the scope of screening and screened another 36 neutralizing antibodies.
Among all 44 monoclonal antibodies tested, only 6 still have potent neutralizing activity against Omi Keron.
They are respectively Yes: sotrovimab, S2K146, S2X324, S2N28, S2X259 and S2H97
.
Among 29 monoclonal antibodies that target specific regions of RBD (receptor binding motifs), 26 have a significant decrease in the neutralizing activity of Omi Keron
.
The researchers also compared the activity of the vaccine or infection-induced antibodies against the Ome Keron pseudovirus and the activity of the pseudovirus from the original new coronavirus from Wuhan
.
The sampling time is 7-10 months after the last injection (except for Johnson & Johnson vaccine) of the vaccine recipient
.
The plasma of convalescent patients or individuals vaccinated with Johnson & Johnson vaccine (only one shot), Sputnik V vaccine or Sinopharm vaccine has low or no neutralizing activity for Omi Keron
.
The neutralizing activity of Moderna, Pfizer-BioNTech and AstraZeneca vaccinators against Omi Keron was 33 times, 44 times and 36 times lower than that of the original isolate of the new crown, respectively
.
Paper link: https:// Omi Keron can escape most of the existing neutralizing antibodies of the new coronavirus, Peking University Xie Xiaoliang and colleagues used a new screening technology to draw A map of mutations in the Omikeron spike protein RBD.
These mutations allow the Omikeron to escape the neutralizing antibody
.
The author screened 247 human neutralizing antibodies and found that Omi Keron can escape more than 85% of the antibodies
.
The authors found that these antibodies can be classified into six categories (A to F) based on their epitopes (antibody binding sites), and that a single mutation on the Omi Keron RBD affects the effectiveness of different categories of antibodies
.
For example, Omi Keron can use the mutations K417N, G446S, E484A, and Q439R to escape class A to D antibodies whose epitopes overlap with ACE2 binding motifs
.
The E and F antibodies that usually have broad-spectrum neutralizing activity against the Sabe virus (the virus genus where the new coronavirus belongs) are less affected by the Omi Keron mutation
.
The author also found that Omi Kejon can greatly destroy the neutralizing activity of antibody drugs etesevimab-bamlanivimab cocktail therapy, REGEN-COV cocktail therapy, cilgavimab-tixagevimab cocktail therapy and aubarvimab antibody
.
However, the monoclonal antibodies sotrovimab and DXP-604 are still useful for Omi Keron, but their effectiveness will be reduced
.
Link to the paper: https:// open for reprinting, welcome to forward to Moments and WeChat groups
1.
1.
529 was named "Omi Keron" and listed as a mutant strain of concern (Variant of Concern, VOC), that is, the new coronavirus variant with the highest risk level
.
In less than 4 weeks, Omi Keron infection has accounted for about 73% of the new coronavirus infections in the United States
.
On December 23, Nature published 5 papers on the effectiveness of vaccines and antibodies against Omicron variants of the new coronavirus
.
Existing new coronavirus vaccines and new coronavirus monoclonal antibodies (proteins that target and neutralize the new coronavirus) work by recognizing the spike protein (S protein) of the new coronavirus, which is also used by the new coronavirus to enter human cells Location
.
The Omi Keron variant has about 32 mutations in the spike protein and is expected to soon replace the currently popular Delta lineage.
However, Omi Keron’s impact on the effectiveness of existing therapies and vaccines is still unclear.
Know
.
The new crown virus Ome Keron variant showed amazing antibody escape, Columbia University David Ho (David Ho) and colleagues reported that the new crown pneumonia (COVID-19) vaccine and therapies are much less effective for Ome Keron
.
The author investigated four major new coronavirus pneumonia vaccines - Pfizer-BioNTech's mRNA vaccine, Moderna's mRNA vaccine, Johnson & Johnson vaccine, and AstraZeneca vaccine - neutralizing Omi Keron in samples from 54 participants The 54 participants were vaccinated with two complete doses of vaccine (15 of them were also vaccinated with Pfizer-BioNTech's mRNA vaccine and Moderna's mRNA vaccine booster)
.
A significant decrease in the effectiveness of anti-Omi Keron has been observed in all vaccine types, including two participants who have been infected with the new coronavirus
.
However, in Pfizer-BioNTech's mRNA vaccine or Moderna's mRNA vaccine booster samples, the reduction in antibody neutralization rate is small
.
The authors also studied the neutralizing activity of 19 monoclonal antibodies against the mutant spike protein of Omi Keron
.
The monoclonal antibodies tested include clinically approved therapeutic antibodies, such as REGN10987 (imdevimab), REGN10933 (casirivimab), COV2-2196 (tixagevimab), COV2-2130 (cilgavimab), LY-CoV555 (bamlanivimab), CB6 (etesevimab) ), Brii-196 (amubarvimab), Brii-198 (romlusevimab) and S309 (sotrovimab)
.
The results showed that 17 of the 19 monoclonal antibodies completely or partially lost their neutralizing ability
.
Only romlusevimab and sotrovimab retained their neutralizing activity
.
The author also reported four new mutations (S371L, N440K, G446S and Q493R) of the Omi Keron spike protein.
These mutations give Omi Keron stronger antibody resistance than other new coronavirus variants
.
Link to the paper: https:// The neutralizing effect of the new crown virus Omi Keron variant has a large escape from the neutralization of antibodies, Olivier Schwartz of the Pasteur Institute in France and colleagues from Belgium An individual in, isolated an Ome Keron virus and analyzed how sensitive the virus is to 9 monoclonal antibodies that are currently approved for clinical use or are still in development
.
As a result, it was found that the Omi Keron mutant strain can completely or partially resist the neutralizing effect of all monoclonal antibodies in the experiment
.
Among them, 5 kinds of antibodies (Bamlanivimab, Etesevimab, Casirivimab, Imdevimab and Regdanvimab) are not effective against Omi Keron; 2 antibodies (Cilgavimab and Andintrevimab) have a lower neutralizing activity against Omi Keron than their activity against delta.
20 times; Sotrovimab's anti-Omi Keron activity is about 3 times lower than its anti-delta activity
.
In the serum collected five months after the second injection of Pfizer-BioNTech's mRNA vaccine (16 people) or AstraZeneca vaccine (18 people), no antiviral activity against Omi Keron was detected
.
From the serum samples collected from 20 Pfizer-BioNTech mRNA vaccine third-injectors, the authors found that the neutralizing activity of Omi Keron increased by 6 times
.
In the serum of 40 recovered individuals (with a history of infection) collected 6 months or 12 months after the onset of symptoms, the neutralizing activity of Omi Keron was either very low or not
.
However, among these recovered individuals, 22 people who received a shot of Pfizer-BioNTech's mRNA vaccine had a higher neutralizing activity in their bodies than those who had received two shots of vaccine without a history of infection
.
These preliminary analyses are all based on the sera of vaccinators or those who have recovered from infection, but the authors pointed out that the sample size of these sera is small, and they only analyzed two vaccines, Pfizer-Biotech and AstraZeneca
.
However, the analysis results show that antibody therapy may need to be quickly adjusted for Omi Keron, and the vaccine booster injection may enhance the neutralizing ability of Omi Keron
.
Link to the paper: https:// Omi Keron's neutralization effect on Pfizer-BioNTech's mRNA vaccine has an obvious but incomplete escape from KwaZulu-Na, South Africa Alex Sigal and colleagues of Thar University used the plasma samples of 19 South African participants who had received two doses of Pfizer-BioNTech's mRNA vaccine to investigate whether Ome Keron had escaped from antibody neutralization
.
Six of the participants had no history of new coronavirus infection
.
The authors observed that, compared with the original strain of the virus, the neutralizing effect of Omi Keron stimulated by the vaccine was reduced by 22 times
.
However, the samples of participants who had a history of new coronavirus infection and were vaccinated retained some of the neutralizing activity against Omi Keron, and its activity level was comparable to that of participants who had only been vaccinated against the original new coronavirus strain.
The level is comparable
.
Link to the paper: https:// Broad-spectrum neutralizing antibodies can cope with the transformation of Omi Keron antigen.
The study by Davide Corti of Vir Biotechnology and colleagues shows that Omeike Evidence that Rong's immune escape ability may be stronger than the previous new coronavirus lineage
.
They tested the binding of the Omi Keron receptor binding domain (RBD) to the human ACE2 receptor-RBD is a part of the spike protein that can help the new coronavirus enter the host cell, and the ACE2 receptor is a major part of RBD Combine goals
.
Studies have shown that compared with the original isolated strain of the new crown, the binding affinity of Omi Keron's RBD and human ACE2 has been enhanced (increased by about 2.
4 times)
.
The author also studied the activity of monoclonal antibodies that have been approved or are under development against the new coronavirus infection against the Omi Keron pseudovirus (a new coronavirus model)
.
Among the eight therapeutic monoclonal antibodies tested in the study, most of them completely lost their neutralizing activity to Omi Keron; the effectiveness of two monoclonal antibodies (combined) was reduced by about 100 times, one monoclonal antibody ( The effectiveness of sotrovimab) has dropped by a factor of three
.
The research team also expanded the scope of screening and screened another 36 neutralizing antibodies.
Among all 44 monoclonal antibodies tested, only 6 still have potent neutralizing activity against Omi Keron.
They are respectively Yes: sotrovimab, S2K146, S2X324, S2N28, S2X259 and S2H97
.
Among 29 monoclonal antibodies that target specific regions of RBD (receptor binding motifs), 26 have a significant decrease in the neutralizing activity of Omi Keron
.
The researchers also compared the activity of the vaccine or infection-induced antibodies against the Ome Keron pseudovirus and the activity of the pseudovirus from the original new coronavirus from Wuhan
.
The sampling time is 7-10 months after the last injection (except for Johnson & Johnson vaccine) of the vaccine recipient
.
The plasma of convalescent patients or individuals vaccinated with Johnson & Johnson vaccine (only one shot), Sputnik V vaccine or Sinopharm vaccine has low or no neutralizing activity for Omi Keron
.
The neutralizing activity of Moderna, Pfizer-BioNTech and AstraZeneca vaccinators against Omi Keron was 33 times, 44 times and 36 times lower than that of the original isolate of the new crown, respectively
.
Paper link: https:// Omi Keron can escape most of the existing neutralizing antibodies of the new coronavirus, Peking University Xie Xiaoliang and colleagues used a new screening technology to draw A map of mutations in the Omikeron spike protein RBD.
These mutations allow the Omikeron to escape the neutralizing antibody
.
The author screened 247 human neutralizing antibodies and found that Omi Keron can escape more than 85% of the antibodies
.
The authors found that these antibodies can be classified into six categories (A to F) based on their epitopes (antibody binding sites), and that a single mutation on the Omi Keron RBD affects the effectiveness of different categories of antibodies
.
For example, Omi Keron can use the mutations K417N, G446S, E484A, and Q439R to escape class A to D antibodies whose epitopes overlap with ACE2 binding motifs
.
The E and F antibodies that usually have broad-spectrum neutralizing activity against the Sabe virus (the virus genus where the new coronavirus belongs) are less affected by the Omi Keron mutation
.
The author also found that Omi Kejon can greatly destroy the neutralizing activity of antibody drugs etesevimab-bamlanivimab cocktail therapy, REGEN-COV cocktail therapy, cilgavimab-tixagevimab cocktail therapy and aubarvimab antibody
.
However, the monoclonal antibodies sotrovimab and DXP-604 are still useful for Omi Keron, but their effectiveness will be reduced
.
Link to the paper: https:// open for reprinting, welcome to forward to Moments and WeChat groups
